

Tell me we've got a plan



INDICATION

CYRAMZA® (ramucirumab) in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.

All materials must be reviewed and approved by your local medical/legal/regulatory teams before use. Before external use, all materials developed must be compliant with local regulations.

SAFETY PLACEHOLDER

mNSCLC

TABLE OF CONTENTS

Exon 21	3	Safety	13–14
		Safety & Tolerability	13
Mechanism of Action (MOA)	4	Treatment Discontinuation	14
The RELAY Trial	5–7	Quality of Life (QoL)	15
Study Design	5		
Target Patients	6	Treatment Planning	16
Baseline Characteristics	7		
Efficacy	8–12	Summary & Indications	18
PFS: ITT Population	8		
PFS: Exon 21	9	Appendix	19
PFS: Exon 19	10		
PFS: Additional Clinical Subgroups	11		
DoR/ORR/DCR	12		